Senior executives from Morgan Stanley (NYSE:MS), now said to be a key consultant to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), called Valeant a “house of cards,” in an e-mail to Allergan, Inc. (NYSE:AGN) management saying “your investors should not want to take their stock.”
Allergan has kicked up its pressure on the stock price of Valeant
Please login to view the rest of this article - Not subscribed? Get our adfree exclusive content for only a few dollars a month. It also helps us fund our operations so think of it as supporting quality journalism.